Epsilon-Aminocaproic Acid Has No Association With Thromboembolic Complications, Renal Failure, or Mortality After Liver Transplantation

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 30, Issue 4, 2016, Pages 917-923

  Nicolau Raducu, Ramona ^a   Ku, Timothy C ^b   Ganier, Donald R ^a   Evans, Brian M ^a   Koveleskie, Joseph ^a   Daly, William J ^a   Fish, Brian ^a   Cohen, Ari J ^a   Reichman, Trevor W ^a   Bohorquez, Humberto E ^a   Bruce, David S ^a   Carmody, Ian C ^a   Loss, George E ^a   Gitman, Marina ^c   Marshall, Thomas ^a   Nossaman, Bobby D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

acute kidney injury; antifibrinolytics; epsilon aminocaproic acid; intracardiac thrombosis pulmonary embolism; liver transplantation; thromboembolic complications

Indexed keywords

AMINOCAPROIC ACID; SODIUM; ANTIFIBRINOLYTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTRACARDIAC THROMBOSIS; INTRAOPERATIVE PERIOD; LIVER TRANSPLANTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURVIVAL RATE; THROMBOEMBOLISM; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; DOSE RESPONSE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; SURVIVAL ANALYSIS;

ACUTE KIDNEY INJURY; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 84977156832     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2015.12.003     Document Type: Article

References (29)

1. 1 Kang, Y., Lewis, J.H., Navalgund, A., et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 66 (1987), 766–773.
2. 2 Kang, Y., Coagulation and liver transplantation. Transplant Proc 25 (1993), 2001–2005.
3. 3 Hu, K.Q., Yu, A.S., Tiyyagura, L., et al. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 96 (2001), 1581–1586.
4. 4 Molenaar, I.Q., Warnaar, N., Groen, H., et al. Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis. Am J Transplant 7 (2007), 185–194.
5. 5 Warnaar, N., Molenaar, I.Q., Colquhoun, S.D., et al. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: A systematic review. J Thrombosis. Haemostasis 6 (2008), 297–302.
6. 6 Xia, V.W., Steadman, R.H., Antifibrinolytics in orthotopic liver transplantation: Current status and controversies. Liver Transpl 11 (2005), 10–18.
7. 7 Fergusson, D.A., Hebert, P.C., Mazer, C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New Engl J Med 358 (2008), 2319–2331.
8. 8 Ray, W.A., Stein, C.M., The aprotinin story—is BART the final chapter?. New Engl J Med 358 (2008), 2398–2400.
9. 9 Food and Drug Administration: 2007 Safety Alerts for Human Medical Products: Trasylol. Available at: (http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095103.htm). Accessed December 13, 2015.
10. 10 Feng, S., Goodrich, N.P., Bragg-Gresham, J.L., et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 6 (2006), 783–790.
11. 11 Matsusaki, T., Hilmi, I.A., Planinsic, R.M., et al. Cardiac arrest during adult liver transplantation: A single institution's experience with 1238 deceased donor transplants. Liver Transpl 19 (2013), 1262–1271.
12. 12 Senzolo, M., Agarwal, S., Zappoli, P., et al. Heparin-like effect contributes to the coagulopathy in patients with acute liver failure undergoing liver transplantation. Liver Int 29 (2009), 754–759.
13. 13 Agarwal, S., Senzolo, M., Melikian, C., et al. The prevalence of a heparin-like effect shown on the thromboelastograph in patients undergoing liver transplantation. Liver Transpl 14 (2008), 855–860.
14. 14 Kellum, J.A., Lameire, N., KDIGO, A.K.I. Guideline Work Group, Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care, 17, 2013, 204.
15. 15 Nicolau-Raducu, R., Gitman, M., Ganier, D., et al. Adverse cardiac events after orthotopic liver transplantation: A cross-sectional study in 389 consecutive patients. Liver Transpl 21 (2015), 13–21.
16. 16 Gologorsky, E., De Wolf, A.M., Scott, V., et al. Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 7 (2001), 783–789.
17. 17 Planinsic, R.M., Hilmi, I.A., Sakai, T., Prevention of intracardiac/pulmonary thrombosis during liver transplantation. Anesth Analg, 103, 2006, 1329.
18. 18 Kikura, M., Levy, J.H., Tanaka, K.A., et al. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 202:216-222; quiz, 2006, A44–45.
19. 19 Chen, R.H., Frazier, O.H., Cooley, D.A., Antifibrinolytic therapy in cardiac surgery. Texas Heart Inst J 22 (1995), 211–215.
20. 20 Mangus, R.S., Kinsella, S.B., Fridell, J.A., et al. Aminocaproic acid (Amicar) as an alternative to aprotinin (trasylol) in liver transplantation. Transplant Proc 46 (2014), 1393–1399.
21. 21 Dalmau, A., Sabate, A., Acosta, F., et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91 (2000), 29–34.
22. 22 Kong, H.Y., Wen, X.H., Huang, S.Q., et al. Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation. World J Surg 38 (2014), 177–185.
23. 23 Borthwick, E., Ferguson, A., Perioperative acute kidney injury: Risk factors, recognition, management, and outcomes. Br Med J, 341, 2010, c3365.
24. 24 Sanchez, E.Q., Gonwa, T.A., Levy, M.F., et al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation. Transplantation 78 (2004), 1048–1054.
25. 25 Narciso, R.C., Ferraz, L.R., Mies, S., et al. Impact of acute kidney injury exposure period among liver transplantation patients. BMC Nephrol, 14, 2013, 43.
26. 26 Nadim, M.K., Genyk, Y.S., Tokin, C., et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: Acute tubular necrosis versus hepatorenal syndrome. Liver Transpl 18 (2012), 539–548.
27. 27 Salami, A., Qureshi, W., Kuriakose, P., et al. Frequency and predictors of venous thromboembolism in orthotopic liver transplant recipients: A single-center retrospective review. Transplant Proc 45 (2013), 315–319.
28. 28 Porte, R.J., Antifibrinolytics in liver transplantation: They are effective, but what about the risk-benefit ratio?. Liver Transpl 10 (2004), 285–288.
29. 29 Sakai, T., Matsusaki, T., Dai, F., et al. Pulmonary thromboembolism during adult liver transplantation: Incidence, clinical presentation, outcome, risk factors, and diagnostic predictors. Br J Anaesth 108 (2012), 469–477.